Clinical trial
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
NCT00003755 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003755 |
|---|---|
| Title | Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor |
| Official title | Phase I Study of R031-7453, a Novell Cell Cycle Inhibitor, Administered as Escalating Oral Doses in Adults With Solid Tumors: 4-Day Schedule |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | MKC-1 |
| Enrollment | 40 |
| Start date | Oct 1, 1998 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2001 |
| First posted | Jun 3, 2004 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: